All In Biotech

Drug Trial Radar · NCT07830238

SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

An Exploratory Clinical Study Evaluating the Safety and Pharmacokinetic Profile of SNC116 in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2030

Study completion Mar 2030

Sponsor

Sponsor type
Industry
Collaborators
The First Hospital of Jilin University
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Interventions

  • SNC116Drug

    Subjects will receive SNC116 injection per different dose level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Evaluation: The incidence rates, type and severity of all adverse eventsTime frame: with 3 months after infusion
  2. Safety Evaluation: DLTTime frame: with 28 days after infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.